3 Top Pharma Growth Stocks to Watch for Future Multibagger Potential: Mankind Pharma, Lupin and Ajanta Pharma
- October 19, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Mankind Pharma Rs 2,275.50. Lupin Rs 1,961.60. Ajanta Pharma Rs 3,329. Market caps from Rs 41,525 crore to Rs 97,264 crore. Data as of 16 Oct 2026.
Quick Answer
Mankind Pharma, Lupin and Ajanta Pharma are the 3 picks in this pharma growth stocks watchlist, with market caps between Rs 41,525 crore and Rs 97,264 crore. Mankind Pharma stands out for the largest market cap at Rs 97,264 crore, while Lupin offers the highest return on equity at 23.76%. PE ratios run from 16.14 to 47.04, so compare each one with its industry PE before investing. All figures are as of 16 October 2026.
Pharma growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Mankind Pharma, Lupin and Ajanta Pharma meet that test, with market caps from Rs 41,525 crore to Rs 97,264 crore and Mankind Pharma offering the largest market cap at Rs 97,264 crore. Strong export sales, branded generics and a fast-growing domestic market give these pharma companies several growth paths.
This list covers listed pharmaceutical companies with complete, verifiable financials, ranked by market capitalisation. Not every name here is a largecap, so the list takes the leading companies of the sector by market capitalisation. Investors screening pharma growth stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Pharma Growth Stocks and Why Do They Attract Multibagger Interest?
Pharma growth stocks are shares of drug makers that are growing sales and profits through exports, branded generics and strong brands in India. Earnings depend on new launches, prescription trends and the cost of making and selling medicines.
A growing and ageing population, rising chronic disease and higher health spending support domestic sales, while export markets add scale. Companies with strong brands, healthy margins and steady launches are the ones investors compare in pharma growth stocks.
Pharma Growth Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 16 October 2026. Lupin combines the lowest PE of the group, 16.14, with the highest return on equity, 23.76%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Mankind Pharma | 2,275.50 | 97,264 | 47.04 | 36.42 | 11.74% | 0.39 | 1,909.70 to 2,642.00 |
| Lupin | 1,961.60 | 89,592 | 16.14 | 36.42 | 23.76% | 0.29 | 1,900.00 to 2,529.50 |
| Ajanta Pharma | 3,329 | 41,525 | 36.59 | 36.35 | 23.33% | 0.06 | 2,380.20 to 3,796.00 |
Mankind Pharma: Quarterly Profit Up 29.12%
Mankind Pharma is one of India’s largest domestic pharmaceutical companies, with strong brands in acute and chronic therapies and a wide field force. It reported FY26 revenue of Rs 14,636.43 crore, up 14.85% year on year, and net profit of Rs 1,938.10 crore. Net profit has compounded at 7.47% a year since FY22, while revenue has grown 16.38% a year. Operating margin was 27.06% in FY26. The debt-to-equity ratio is 0.39.
In the June 2026 quarter, revenue rose 11.65% to Rs 4,075.59 crore and net profit grew 29.12% to Rs 574.09 crore. Domestic institutions raised their holding from 11.50% in June 2025 to 15.39% in June 2026. The stock trades at a PE of 47.04 against an industry PE of 36.42.
Lupin: Revenue Up 26.76% in FY26
Lupin is a global pharmaceutical company with a large presence in the United States, India and other markets across generics, branded drugs and respiratory products. It reported FY26 revenue of Rs 29,038.95 crore, up 26.76% year on year, and net profit of Rs 5,355.47 crore, up 61.98%. Revenue has compounded at 14.98% a year since FY22. Operating margin was 31.06% in FY26. The debt-to-equity ratio is 0.29.
The stock trades at a PE of 16.14 against an industry PE of 36.42, below the sector average, with a return on equity of 23.76%. In the June 2026 quarter, revenue rose 32.45% to Rs 8,407.21 crore and net profit grew 16.01% to Rs 1,416.98 crore. The share price has gained 111.00% over five years. Foreign investors raised their holding from 21.25% in June 2025 to 22.42% in June 2026.
Ajanta Pharma: Return on Equity of 23.33%
Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.
In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026. The stock trades at a PE of 36.59 against an industry PE of 36.35, with a return on equity of 23.33%.
Pharma Growth Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these pharma growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Mankind Pharma | 14,636.43 | 1,938.10 | 14.85% | 16.38% | 11.65% | 27.42% |
| Lupin | 29,038.95 | 5,355.47 | 26.76% | 14.98% | 32.45% | 31.40% |
| Ajanta Pharma | 5,624.93 | 1,056 | 18.60% | 12.94% | 27.68% | 30.41% |
Check the Univest Screener for live data on these pharma growth stocks
Institutional Holding in Mankind Pharma, Lupin and Ajanta Pharma
Institutional holding shows who is backing these pharma growth stocks alongside the promoter. The table uses the latest reported quarter for each. Lupin has the deepest institutional backing, with FII and DII together holding 47.07% as of June 2026. Domestic institutions increased their holding over the past year in Mankind Pharma (from 11.50% to 15.39%) and Ajanta Pharma (from 17.90% to 21.94%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Mankind Pharma | 72.63% | 9.45% | 15.39% | 2.53% | June 2026 |
| Lupin | 46.85% | 22.42% | 24.65% | 6.08% | June 2026 |
| Ajanta Pharma | 63.47% | 7.63% | 21.94% | 6.96% | September 2026 |
Risks to Weigh in Pharma Growth Stocks
Being careful with pharma growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Pharma earnings can vary with drug pricing in export markets and regulatory checks.
- Raw material and currency movements can influence margins.
- Valuation: Mankind Pharma trades at a PE of 47.04 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Pharma Growth Stocks
Picking from pharma growth stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (36.35 to 36.42) and ask whether the growth rate justifies any gap.
- Track revenue growth, the operating margin and new product launches in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Mankind Pharma, Lupin and Ajanta Pharma live prices.
Conclusion
Among pharma growth stocks, Mankind Pharma stands out for the largest market cap at Rs 97,264 crore, Lupin for the highest return on equity at 23.76% and Ajanta Pharma for the fastest profit growth, 10.33% a year since FY22. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing pharma growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Pharma Growth Stocks to Watch
Which are the best pharma growth stocks to watch for multibagger potential?
Ans. Mankind Pharma, Lupin and Ajanta Pharma are the 3 names this list highlights, with market caps of Rs 97,264 crore, Rs 89,592 crore and Rs 41,525 crore respectively. Mankind Pharma is notable for the largest market cap at Rs 97,264 crore. Lupin stands out for the highest return on equity at 23.76%. Ajanta Pharma offers the fastest profit growth, 10.33% a year since FY22. These are watchlist names for pharma growth stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Lupin a good stock for long-term investors?
Ans. Lupin has a return on equity of 23.76%, a PE of 16.14 against an industry PE of 36.42 and a market cap of Rs 89,592 crore. FY26 revenue rose 26.76%, and June 2026 quarter net profit grew 16.01%. Long-term returns in pharma growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Ajanta Pharma become a multibagger from here?
Ans. Ajanta Pharma has already gained 125.31% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in pharma growth stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 10.33% a year since FY22, and FY26 revenue rose 18.60%. At a PE of 36.59 against an industry PE of 36.35, valuation should be checked against that growth before investing.
What is the market cap of Mankind Pharma, Lupin and Ajanta Pharma?
Ans. As of 16 October 2026, Mankind Pharma has a market cap of Rs 97,264 crore, Lupin has a market cap of Rs 89,592 crore and Ajanta Pharma has a market cap of Rs 41,525 crore. Mankind Pharma is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on pharma growth stocks.
What are the risks of investing in pharma growth stocks?
Ans. The main risks are price changes in export markets, regulatory inspections of plants and currency swings. Companies with varied products and markets handle these better. Mankind Pharma trades at a PE of 47.04 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Mankind Pharma trading at a PE of 47.04?
Ans. Mankind Pharma’s PE of 47.04 compares with an industry PE of 36.42. The market is paying a premium for latest-quarter profit growth of 29.12%, which also means the stock is more sensitive if growth slows. Investors in pharma growth stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Mankind Pharma, Lupin and Ajanta Pharma?
Ans. As of the latest reported quarter, FII and DII together hold 24.84% of Mankind Pharma (9.45% and 15.39%), 47.07% of Lupin (22.42% and 24.65%) and 29.57% of Ajanta Pharma (7.63% and 21.94%). Rising institutional holding is a useful signal in pharma growth stocks, though it should be read with earnings trends rather than on its own.
